120 min达雷妥尤单抗快速输注的观察及护理

打开文本图片集

Observation and nursing care of 120 min rapid infusion of daretuumab

HAO Rui1，2， DONG Yanyan1，2， XU Baonan1，2， WANG Wen1，2*

1.Hospital of Hematology， Chinese Academy of Medical Sciences （Institute of Hematology， Chinese Academy of Medical Sciences）/ National Key Laboratory of Blood and Health/National Center for Clinical Medical Research of Hematological Diseases/Haihe Laboratory of Cell Ecology， Tianjin 300020 China；2.Tianjin Institute of Medical Health

*Corresponding Author  WANG Wen， E⁃mail：wangwen@ihcams.as.cn

Abstract    Objective： To investigate the safety and tolerability of rapid infusion of daratumumab and to provide support for the feasibility of rapid infusion protocols in chemotherapy and day hospital settings and in clinical nursing. Methods： Rapid infusion of daratumumab was administered （completed within 120 minutes： total infusion volume of 500 mL， with an initial infusion rate of 200 mL/h for the first 30 minutes （20% of the total volume， 100 mL）；the infusion rate was adjusted to 270 mL/h for the remaining 90 minutes to administer the remaining 80% （400 mL） of the fluid.Continuous electrocardiographic monitoring was used to observe and record vital signs. Results： Among the 149 patients observed， who received a total of 1 362 daratumumab treatments， only 11 patients（0.81%） resulted in grade 1 or 2 infusion⁃related reactions （IRR），and no patients experienced grade 3 or higher IRRs. Conclusions： For patients who did not experience grade 3 or higher IRR during their first and second standard infusions， the 120-minute rapid infusion method of daratumumab is feasible. It significantly shortens infusion time， reduces patient hospital stays and costs， enhances patient comfort and convenience， and alleviates nurses' workload.

Keywords    multiple myeloma； daletumab； rapid infusion method； infusion related reaction； nursing； satisfaction

摘要  目的：探讨达雷妥尤单抗快速输注的安全性及耐受性，为快速输注方案在各中心治疗和日间病房应用的可行性及临床护理提供支持。（剩余7649字）